Analyst’s Disclosure: I/we have a beneficial long position in the shares of NKTR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any i ...

Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis [Accessibility Statement] Skip NavigationSAN FRANCISCO, Feb. 17, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced an academic research collaboration with the University of California, San Francisco (UCSF) and Stephen L. Hauser, M.D., Robert A. Fishman Distinguished Professor of Neurology and Director of the UCSF ...

Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares [Accessibility Statement] Skip NavigationSAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public offering of $460 million of shares of its common stock and, in lie ...

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to avoid access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Core Viewpoint - Nektar Therapeutics has announced the pricing of an upsized public offering of $400 million, which includes common stock and pre-funded warrants, aimed at supporting its clinical development and general corporate purposes [1][2] Group 1: Offering Details - Nektar is offering 6,603,449 shares of common stock at a price of $58.00 per share and 293,103 pre-funded warrants at a price of $57.9999 each, leading to expected gross proceeds of approximately $400 million before expenses [1] - The underwriters have a 30-day option to purchase an additional 1,034,482 shares at the public offering price [1] - The offering is expected to close on February 13, 2026, subject to customary conditions [1] Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including research and development, clinical development (notably Phase 3 trials for rezpegaldesleukin), and manufacturing costs [1] Group 3: Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for autoimmune and chronic inflammatory diseases [1] - The lead product candidate, rezpegaldesleukin, is being evaluated in multiple clinical trials for conditions such as atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus [1] - Nektar's pipeline includes additional candidates like NKTR-0165, NKTR-0166, and NKTR-422, as well as NKTR-255, which is designed to enhance the immune system's ability to combat cancer [1]

Core Viewpoint - Nektar Therapeutics (NKTR) shares experienced a significant increase of 51.1% in the last trading session, closing at $56, following the announcement of positive clinical data [1][2]. Group 1: Company Performance - The stock's recent rally was driven by positive data from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study, which evaluated rezpeg in patients with moderate-to-severe atopic dermatitis, showing durable responses across key disease measurements [2]. - The safety profile of rezpeg during the maintenance phase was consistent with that observed in the induction phase of the study [2]. - Nektar is expected to report a quarterly loss of $2.69 per share, reflecting a year-over-year decline of 19.6%, with revenues projected at $9.06 million, down 68.9% from the previous year [3]. Group 2: Market Sentiment and Estimates - The consensus EPS estimate for Nektar has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4]. - Nektar currently holds a Zacks Rank of 3 (Hold), while another company in the same industry, Merck KGaA, has a Zacks Rank of 2 (Buy) and finished the last trading session 1.2% higher [5][6].

Core Insights - Nektar Therapeutics' stock experienced a significant surge following the release of long-term data indicating that its experimental eczema therapy provides sustained and deepening disease control over one year, enhancing its competitive position in the atopic dermatitis market [1] Group 1: Clinical Data and Efficacy - The 36-week blinded maintenance period of the 52-week REZOLVE-AD study showed that the dosing regimens resulted in sustained disease control, with notable improvements in Eczema Area Severity Index (EASI) scores and Itch Numerical Rating Scale (NRS) responses [2][3] - A significant proportion of patients achieved new EASI-75, EASI-90, Itch NRS, and validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD) responses at Week 52, indicating enhanced disease control with prolonged therapy and less frequent dosing [4] - Monthly maintenance dosing increased EASI-100 response from 4% to 22%, while quarterly dosing increased it from 9% to 18% among re-randomized patients [5] Group 2: Analyst Upgrades and Market Position - William Blair upgraded Nektar Therapeutics to Outperform, citing the deepening of response and durability of the therapy as key factors [6] - The analyst noted that approximately 20% of patients achieved complete disease clearance (EASI-100) after re-randomization, with about 30% achieving this among those who had a prior response [6] - EASI-75 and EASI-90 scores showed remarkable similarity, with quarterly dosing maintaining a higher response rate compared to competitor datasets [7] Group 3: Financial Developments - Nektar Therapeutics initiated a public offering to raise $300 million through equity [8] - The stock closed at $56.00, reflecting a 51.07% increase in regular trading, and continued to rise to $59.10 in early trading [8]

Core Viewpoint - The conference call is focused on discussing the maintenance data of REZOLVE-AD, a treatment for atopic dermatitis, with insights from industry experts [1]. Group 1: Company Overview - Nektar Therapeutics is hosting an analyst and investor event to present findings related to REZOLVE-AD [1]. - Key executives participating in the call include Howard Robin (President and CEO), Dr. Jonathan Zalevsky (Chief Research and Development Officer), and Dr. Mary Tagliaferri (Chief Medical Officer) [2]. Group 2: Future Outlook - The company plans to make forward-looking statements regarding the therapeutic potential and future development plans for rezpegaldesleukin, as well as the timing for future clinical data presentations [3]. - These forward-looking statements are subject to uncertainties and risks that may affect actual results [4].

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Nektar Therapeutics (NasdaqCM:NKTR) Conference Call Summary Company Overview - **Company**: Nektar Therapeutics - **Focus**: Development of Rezpegaldesleukin (ResPEG) for the treatment of atopic dermatitis and other conditions Key Points from the Conference Call Industry and Product Insights - **Therapeutic Area**: Atopic dermatitis, with a focus on patients with comorbid asthma, which represents 25% of the overall population [3][12] - **Mechanism of Action**: ResPEG utilizes a novel TREG mechanism to promote immune resolution, differentiating it from traditional cytokine-blocking therapies [8][9] - **Clinical Trials**: Phase 2b Resolve AD study results were discussed, highlighting the efficacy and safety of ResPEG over a 36-week maintenance period [3][15] Clinical Data Highlights - **Efficacy Results**: - 74% of patients on the 24 microgram per kilogram monthly regimen maintained their EASI-75 response at week 52 [22] - 80% of patients on the monthly dosing regimen maintained an EZ90 response, compared to 78% on the quarterly regimen [23] - New responders were identified, with 41% and 40% of non-responders converting to vIGA responders at the end of 52 weeks for monthly and quarterly regimens, respectively [29] - A five-fold increase in patients achieving complete disease clearance (EASI-100) was observed, with 30% of patients achieving this by the end of 52 weeks [31] Safety Profile - **Adverse Events**: - Discontinuation due to adverse events was low at 3.5%, with no new safety signals identified [32] - Injection site reactions (ISRs) were the most common adverse events, with a frequency of 0.7% leading to treatment discontinuation [32][70] - The incidence of ISRs decreased during the maintenance phase compared to induction [33] Future Development Plans - **Phase 3 Trials**: Plans to initiate Phase 3 trials in Q2 2026, targeting a BLA submission in 2029 [5][36] - **Patient Population**: Trials will include biologic-naïve patients and those who have received prior biologics or JAK inhibitors [37] Competitive Landscape - **Comparison with Dupilumab**: ResPEG's maintenance efficacy was shown to be comparable or superior to Dupilumab, particularly in maintaining vIGA responses [25][26] - **Market Positioning**: ResPEG is positioned as a first-line treatment option, especially for patients with comorbid asthma, which is a significant differentiator from other therapies [44][52] Expert Opinions - **Clinical Adoption**: Experts expressed optimism about using ResPEG as a first-line treatment due to its efficacy and safety profile, particularly for difficult-to-treat patients [42][48] Upcoming Milestones - **Data Presentations**: Additional data from the Resolve AD study and other ongoing studies are expected to be presented at medical meetings in the coming year [38] Conclusion Nektar Therapeutics is advancing its clinical development of ResPEG for atopic dermatitis, demonstrating promising efficacy and safety data. The upcoming Phase 3 trials and the potential for a BLA submission in 2029 position the company favorably in the competitive landscape of dermatological therapies.